BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2003

View Archived Issues

Chiron acquires rights to aerosolized ciclosporin from Novartis

Read More

Methods of detecting and treating cancer based on the Septin9 (MSF) gene

Read More

Bridged ketolides designed at Enanta to overcome bacterial resistance

Read More

New data suggest a role for statins in the treatment of Alzheimer's disease

Read More

ALA reported to improve neuropathic symptoms in diabetes

Read More

Procter & Gamble describes new inhibitors of cytokine production

Read More

Tyrosine kinase inhibitors and their use in cancer, angiogenesis, etc., claimed by Allergan

Read More

Yissum patent covers new agents for cancer, lipid storage disorders

Read More

Novel tryptase inhibitors under study at Boehringer Ingelheim

Read More

Cannabinoid CB1 antagonists in early development at Solvay

Read More

BMS researchers discover new inhibitors of MMP, TACE and/or aggrecanase

Read More

U.S./Japanese group identifies elastase release inhibitors

Read More

Erythromycin antibiotics prepared and tested at Ortho-McNeil

Read More

Novartis claims novel ACE/NEP inhibitors with utility in hypertension therapy

Read More

Teijin and Kyorin abandon business integration plans

Read More

Preliminary results from phase III trial of RSR-13 in brain metastases

Read More

Phase III RESIST trials begin for tipranavir

Read More

FDA approves Enteryx technology for GERD

Read More

Liprostin trial planned in critical limb ischemia and intermittent claudication

Read More

Indevus licenses rights to aminocandin

Read More

Cinacalcet demonstrates efficacy in dialysis patients with elevated parathyroid hormone

Read More

Enrollment completed in phase II study of ThGRF

Read More

Texas Biotechnology acquires Icos interest in partnership

Read More

NIH licensing opportunity: methods of inhibiting amino acid formation and tumor angiogenesis

Read More

Benzoylalkylindolepyridinium compounds for HIV available from NIH

Read More

Potential new immunosuppressant for use in transplantation isolated from Chinese herbs

Read More

Another major launch announced for Crestor

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing